Literature DB >> 29744522

[Impact of thyroid diseases on bone].

E Tsourdi1,2, F Lademann1,2, H Siggelkow3,4.   

Abstract

Thyroid hormones are key regulators of skeletal development in childhood and bone homeostasis in adulthood, and thyroid diseases have been associated with increased osteoporotic fractures. Hypothyroidism in children leads to an impaired skeletal maturation and mineralization, but an adequate and timely substitution with thyroid hormones stimulates bone growth. Conversely, hyperthyroidism at a young age accelerates skeletal development, but may also cause short stature because of a premature fusion of the growth plates. Hypothyroidism in adults causes an increase in the duration of the remodeling cycle and, thus, leads to low bone turnover and enhanced mineralization, but an association with a higher fracture risk is less well established. In adults, a surplus of thyroid hormones enhances bone turnover, mostly due to an increased bone resorption driven by osteoclasts. Thus, hyperthyroidism is a well-recognized cause of high-bone turnover secondary osteoporosis, resulting in an increased susceptibility to fragility fractures. Subclinical hyperthyroidism, especially resulting from endogenous disease, also has an adverse effect on bone mineral density and is associated with fractures. In most patients with overt or subclinical hyperthyroidism restoration of the euthyroid status reverses bone loss. In postmenopausal women who receive thyroid-stimulating hormone suppression therapy because of thyroid cancer, antiresorptive treatments may be indicated. Overall, extensive data support the importance of a euthyroid status for bone mineral accrual and growth in childhood as well as maintenance of bone health in adulthood.

Entities:  

Keywords:  Bone diseases, metabolic; Hyperthyroidism; Hypothyroidism; Osteoporosis; Risk, fractures, bone

Mesh:

Year:  2018        PMID: 29744522     DOI: 10.1007/s00108-018-0436-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  30 in total

1.  Long-term growth in juvenile acquired hypothyroidism: the failure to achieve normal adult stature.

Authors:  S A Rivkees; H H Bode; J D Crawford
Journal:  N Engl J Med       Date:  1988-03-10       Impact factor: 91.245

2.  Thyroid hormone stimulation of osteocalcin gene expression in ROS 17/2.8 cells is mediated by transcriptional and post-transcriptional mechanisms.

Authors:  C H Gouveia; J J Schultz; A C Bianco; G A Brent
Journal:  J Endocrinol       Date:  2001-09       Impact factor: 4.286

3.  Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism.

Authors:  H Pantazi; P D Papapetrou
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

4.  Longitudinal growth, sexual maturation and final height in patients with congenital hypothyroidism detected by neonatal screening.

Authors:  M Salerno; M Micillo; S Di Maio; D Capalbo; P Ferri; T Lettiero; A Tenore
Journal:  Eur J Endocrinol       Date:  2001-10       Impact factor: 6.664

5.  Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism.

Authors:  L Mosekilde; F Melsen; J P Bagger; O Myhre-Jensen; N Schwartz Sorensen
Journal:  Acta Endocrinol (Copenh)       Date:  1977-07

6.  Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis.

Authors:  J Faber; A M Galløe
Journal:  Eur J Endocrinol       Date:  1994-04       Impact factor: 6.664

7.  Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism.

Authors:  C J Rosen; R A Adler
Journal:  J Clin Endocrinol Metab       Date:  1992-12       Impact factor: 5.958

8.  Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism.

Authors:  Elena Tsourdi; Franziska Lademann; Michael S Ominsky; Eddy Rijntjes; Josef Köhrle; Barbara M Misof; Paul Roschger; Klaus Klaushofer; Lorenz C Hofbauer; Martina Rauner
Journal:  Endocrinology       Date:  2017-11-01       Impact factor: 4.736

9.  Risk for fracture in women with low serum levels of thyroid-stimulating hormone.

Authors:  D C Bauer; B Ettinger; M C Nevitt; K L Stone
Journal:  Ann Intern Med       Date:  2001-04-03       Impact factor: 25.391

10.  Subclinical thyroid dysfunction and fracture risk: a meta-analysis.

Authors:  Manuel R Blum; Douglas C Bauer; Tinh-Hai Collet; Howard A Fink; Anne R Cappola; Bruno R da Costa; Christina D Wirth; Robin P Peeters; Bjørn O Åsvold; Wendy P J den Elzen; Robert N Luben; Misa Imaizumi; Alexandra P Bremner; Apostolos Gogakos; Richard Eastell; Patricia M Kearney; Elsa S Strotmeyer; Erin R Wallace; Mari Hoff; Graziano Ceresini; Fernando Rivadeneira; André G Uitterlinden; David J Stott; Rudi G J Westendorp; Kay-Tee Khaw; Arnuf Langhammer; Luigi Ferrucci; Jacobijn Gussekloo; Graham R Williams; John P Walsh; Peter Jüni; Drahomir Aujesky; Nicolas Rodondi
Journal:  JAMA       Date:  2015-05-26       Impact factor: 56.272

View more
  1 in total

Review 1.  Clinical Characteristics and Long-Term Recombinant Human Growth Hormone Treatment of 18q- Syndrome: A Case Report and Literature Review.

Authors:  Shanshan Liu; Meiping Chen; Hongbo Yang; Shi Chen; Linjie Wang; Lian Duan; Huijuan Zhu; Hui Pan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-09       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.